Please ensure Javascript is enabled for purposes of website accessibility

Should Investors Worry About This Announcement From Moderna?

By Adria Cimino - Apr 3, 2021 at 6:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A key member of the Moderna team is saying goodbye.

In this Motley Fool Live video recorded on March 26, healthcare and cannabis bureau chief Corinne Cardina and contributor Adria Cimino discuss the upcoming departure of Moderna's (MRNA -4.04%) chief medical officer.

Corinne Cardina: In February, Moderna announced that its chief medical officer is planning to leave the company starting in September. This person has spent six years at Moderna, and they're going to be looking for a new CMO. For a company that's really just celebrating its first commercial success, is this a loss of institutional knowledge? Is it a concern for investors?

Adria Cimino: It's definitely a loss. It definitely is. Tal Zaks who oversees clinical development and regulatory affairs -- losing him is definitely a big loss. I think it's a concern for investors as far as we want to see who is going to take over in that role and how this new person, what their priorities are going to be. Because in this role, you're responsible for clinical development strategy. That's a really big thing. Overseeing analysis of trial data, communicating with health authorities. This is a really, really important thing. I'm expecting that Moderna is going to continue along on the path that Tal Zaks established. But it's still a change, so whenever a change like this comes, it's worth it to really pay attention. Especially at a key point. As we said, we have this new vaccine on the market, Moderna is close to market with potential boosters. There are four of their phase 2 or phase 3 projects in the works. There are also exciting new projects. The company spoke just recently, they just launched work on HIV and flu vaccines. All of this, this new person is going to have to handle and develop strategy, so it's definitely something to watch. No worries for the moment, but something to watch.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
$132.06 (-4.04%) $-5.56

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.